MR [Mindray Medical International] UPLOAD: (Original Filing)
[]
CO [China Cord Blood] 6-K: (Original Filing)
[EXECUTION VERSION CHINA CORD BLOOD CORPORATION 7% SENIOR CONVERTIBLE NOTE Original Principal Amount: US$50,000,000 Company Holder Principal and Issuance Date and Note Notes Other Notes Registration Rights Agreement FOR VALUE RECEIVED, China Cord Blood Corporation, an exempted company with limited liability incorporated in the Cayman Islands (the “ 1. Rank pari passu 2. Maturity Maturity Date (a) Subject to the] [EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT between CHINA CORD BLOOD CORPORATION and GOLDEN MEDITECH HOLDINGS LIMITED Dated October 3, 2012 TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THIS AGREEMENT 5 Section 3 MANDATORY REGISTRATION 5 Section 4 DEMAND REGISTRATION RIGHTS 8 Section 5 INCIDENTAL OR “PIGGY-BACK” REGISTRATION 9 Section 6 UNDERWRITTEN OFFERINGS 9 Section] [China Cord Blood Corporation Announces Completion of $50 Million Convertible Note Financing with Golden Meditech HONG KONG, China, October 3, 2012 China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), the first and largest cord blood banking operator in China, announced that it has successfully completed the previously announced The board of directors of CCBC has appointed Mr. Yuen]
CO [China Cord Blood] 6-K: EXECUTION VERSION CHINA CORD BLOOD CORPORATION 7% SENIOR
[EXECUTION VERSION CHINA CORD BLOOD CORPORATION 7% SENIOR CONVERTIBLE NOTE Original Principal Amount: US$50,000,000 Company Holder Principal and Issuance Date and Note Notes Other Notes Registration Rights Agreement FOR VALUE RECEIVED, China Cord Blood Corporation, an exempted company with limited liability incorporated in the Cayman Islands (the “ 1. Rank pari passu 2. Maturity Maturity Date (a) Subject to the] [EXECUTION VERSION REGISTRATION RIGHTS AGREEMENT between CHINA CORD BLOOD CORPORATION and GOLDEN MEDITECH HOLDINGS LIMITED Dated October 3, 2012 TABLE OF CONTENTS Page Section 1 DEFINITIONS 1 Section 2 GENERAL; SECURITIES SUBJECT TO THIS AGREEMENT 5 Section 3 MANDATORY REGISTRATION 5 Section 4 DEMAND REGISTRATION RIGHTS 8 Section 5 INCIDENTAL OR “PIGGY-BACK” REGISTRATION 9 Section 6 UNDERWRITTEN OFFERINGS 9 Section] [China Cord Blood Corporation Announces Completion of $50 Million Convertible Note Financing with Golden Meditech HONG KONG, China, October 3, 2012 China Cord Blood Corporation (NYSE: CO) (“CCBC” or the “Company”), the first and largest cord blood banking operator in China, announced that it has successfully completed the previously announced The board of directors of CCBC has appointed Mr. Yuen]
OIIM [O2MICRO INTERNATIONAL] 6-K: (Original Filing)
[O2Micro Revises Third Quarter 2012 Financial Guidance 2 ® GEORGE TOWN, Grand Cayman, Oct. 3, 2012 (GLOBE NEWSWIRE) -- O The reduction in anticipated revenue for the third quarter is primarily the result of broad-based weakness in demand in the company's end markets. 2 2 2 Sterling Du, Chairman and CEO of O No conference call will be held in]
OIIM [O2MICRO INTERNATIONAL] 6-K: O2Micro Revises Third Quarter 2012 Financial Guidance 2
[O2Micro Revises Third Quarter 2012 Financial Guidance 2 ® GEORGE TOWN, Grand Cayman, Oct. 3, 2012 (GLOBE NEWSWIRE) -- O The reduction in anticipated revenue for the third quarter is primarily the result of broad-based weakness in demand in the company's end markets. 2 2 2 Sterling Du, Chairman and CEO of O No conference call will be held in]
OIIM [O2MICRO INTERNATIONAL] 6-K: (Original Filing)
[O2Micro Revises Third Quarter 2012 Financial Guidance 2 GEORGE TOWN, Grandyman, Oct. 3, 2012 (GLOBE NEWSWIRE) -- O The reduction in anticipated revenue for the third quarter is primarily the result of broad-based weakness in demand in thempany's end markets. 2 2 2 Sterling Du, Chairman and CEO of O]
TPI [TIANYIN PHARMACEUTICAL] 8-K: (Original Filing)
[TPI Reports Fiscal Year 2012 Financial Results CHENGDU, China, September 28, 2012 Tianyin Pharmaceutical Inc. (NYSE Amex: TPI), a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the fiscal year 2012. Fiscal Year 2012 Ended June 30, 2012 Financial Highlights: ● FY2012 revenue delivered] [Tianyin Pharmaceutical Co., Inc. Fiscal 2012 Earnings Call September 28, 2012 Operator: I would now like to turn the conference over to our host, Dr. James Tong, Chief Financial Officer. Please go ahead, sir. Dr. James Tong: Fiscal year 2012 financial highlights. Revenue delivered $69.6 million, compared with $95.2 million in fiscal year 2011. Operating income delivered $8.5 million, compared] [CURRENT REPORT FOR ISSUERS SUBJECT TO THE FORM 8-K CURRENT REPORT September 28, 2012 Date of Report (Date of Earliest Event Reported) Tianyin Pharmaceutical Co, Inc. Delaware 000-52236 20-4857782 (State or other jurisdiction of incorporation) (IRS Employer Identification No.) 23rd Floor, Unionsun Yangkuo Plaza, No. 2, Block 3 South Renmin Road Chengdu, P. R. China, 610041 +011-86-28-8615-4737 o o o]
